We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Benchmark Holdings Plc | BMK | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 45.50 | 08:17:15 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 45.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 21/2/2024 16:07 by edmonda Q1 Results - Investor Presentation video recording - 15 February 2024Trond Williksen, CEO, and Septima Maguire, CFO of Benchmark Holdings hosted an Investor Presentation following publication of their Q1 results for the period to 31 Dec 2023. Revenues were £40.5m for the quarter, 26% below a particularly strong Q1 FY23, but 11% above Q4 FY23, maintaining quarterly momentum. In Genetics, management discussed solid performance in the core salmon business and progress in growth vectors. In Advanced Nutrition, the company posted strong performance in Europe and in the Health division significant steps have been taken to transition to new business model for Ectosan® Vet and CleanTreat®. Watch the full presentation for more details on period highlights and operational performance per division, including a Financial overview and an update on Outlook. The video has been divided into chapters, as below: 0:00:03 Introduction 0:00:36 Overview of Q1 & period highlights 0:05:40 Operational Update - Genetics 0:13:28 Operational Update - Advanced Nutrition 0:17:47 Operational Update - Health 0:23:46 Financial Update 0:30:26 Outlook 0:33:23 Questions & Answers Link to video: |
Posted at 05/12/2023 09:42 by edmonda Investor Presentation video recording - 29 November 2023 (FY Results webinar)The management of Benchmark Holdings discussed revenue growth and improved profitability for the full year. They touched on the focus they've put into turning around the genetics business in Chile, alongside ameliorating the capital cost of running the CleanTreat boats and driving further take up of Ectosan. The team also provided a detailed financial update, commentary on the 2024 outlook, and answered a range of questions submitted by viewers. Benchmark Holdings plc is an aquaculture biotechnology company and the presenters are Trond Williksen, CEO, and Septima Maguire, CFO. The full video has been divided into chapters, as below: 0:00:42 Highlights of FY / Q4 0:08:44 Operational Update: Genetics 0:15:05 Operational Update: Advanced Nutrition 0:17:33 Operational Update: Health 0:21:31 Financial Update 0:33:00 Outlook 2024 & summary of Benchmark 0:39:39 Questions & Answers Link to video: |
Posted at 29/8/2023 09:46 by edmonda Full video here: Benchmark Holdings plc, the aquaculture biotechnology company, hosted an investor presentation following publication of their Q3 results (period to 30th June 2023). Trond Williksen, CEO, and Septima Maguire, CFO took investors through details of the key operational and financial highlights in the period, which included continued growth in Genetics, offset by the impact of weak shrimp markets on Advanced Nutrition. The management team answered a wide range of investor questions and discussed the outlook for each business division. The full video has been divided into chapters as below: 0:00:03 Introduction & Agenda 0:00:31 Highlights 0:06:19 Operational Update (Genetics) 0:16:38 Operational Update (Advanced Nutrition) 0:20:20 Operational Update (Health) 0:24:53 Financial Update 0:32:21 Outlook 0:39:15 Questions & Answers |
Posted at 29/8/2023 09:44 by edmonda New note and Investor Presentation recording (see full details below)For the three months to 30th June 2023, Benchmark Holdings reported revenue of £34.3m, -5.5%YoY (currency-adjusted -1%YoY), as 10%YoY growth in Genetics (42% of total) was offset by the impact of reduced demand in global shrimp markets, resulting in a 17%YoY decline in Advanced Nutrition revenues (47% of total). Adjusted EBITDA1 declined 23%YoY (£5.1m), a 14.8% margin (Q3 22: 18.1%); on a currency-adjusted basis -13%YoY. Net operating cash inflow of £1.7m contrasted with £(1.0)m outflow in Q3 22, with net debt of £45.7m (FY22: £59.3m) and healthy cash reserves of £32.9m. Q3 under-performance in the Advanced Nutrition business area indicates a revision to our full year FY23 outlook and the basis for FY24 estimates; a 7.2% reduction in our FY23 (adj.) EBITDA outlook and -7.2% for FY24. We maintain our fair value at 63p/share, backed by sound cashflow management, confidence in Genetics salmon eggs demand and production capacity and prospects for Benchmark’s Ectosan®Vet and Clean Treat® treatments. Link to research report: |
Posted at 24/5/2023 15:39 by murdo mcsponge In the light of the Q figs released, what on earth justifies a 5% drop in the Stock's price, and the sale of over 7 million shares? I presume the sales are by AIM holders which would go to prove that UK investors just don't understand The Company and its products and services, and their position in what might be called a "Sunrise" Industry. No wonder The Board decided to focus on The Oslo Exchange. The Norwegians really understand Aquaculture, and have made fortunes out of it. |
Posted at 28/2/2023 12:12 by edwardt well those results look pretty good to me. i guess until this goes to the main list and uk small cap investors sell down - we won't get a pop higher but the fundamentals infer it is a coiled spring? |
Posted at 01/12/2022 09:47 by murdo mcsponge Judging by the information sent out by The Company, UK Shareholders are about to be screwed. There is a Private Placement taking place on the Norwegian Market, which UK Investors are excluded from. This is apparently a condition of listing on the Oslo Market. Considering it is UK shareholders who have carried The Company to this point, this seems to me like theft, if the opportunity to participate is being denied to UK investors. It is said that a decision has still to be reached on whether the AIM listing in London will be continued. My guess is that the decision has already been made and the AIM listing will be discontinued. Is such activity legal? |
Posted at 27/4/2022 11:29 by edmonda Save the Date! Investor Presentation - 18th MayBenchmark Holdings plc, the aquaculture biotechnology company, will be conducting an investor webinar following publication of their Q2 and Interim results. The online presentation will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO. This event will take place at 2.00pm on Wednesday 18th May. The webinar is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end. Sign up here: |
Posted at 23/2/2022 18:26 by murdo mcsponge ...and the Market Price falls. Strange creatures some investors. |
Posted at 23/2/2022 09:34 by edmonda Benchmark Holdings - Q1 Results - Investor Presentation video (22nd February)Trond Williksen, CEO, and Septima Maguire, CFO of Benchmark Holdings plc presented the highlights of their financial and operational performance of Q1 to investors. They discussed insights into the 2022 outlook and answered investor questions around inflationary input costs and utilisation rates of CleanTreat vessels. The full video presentation is divided into chapters for ease of viewing: 0:00:03 Q1 overview and operational highlights (CEO, Trond Williksen) 0:14:02 Financial Review (Septima Maguire, CFO) 0:24:15 Current trading & outlook (CEO, Trond Williksen) 0:28:13 Question & Answer session (with concluding comments) Link to video presentation: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
